Paul Abrams received his BA in Political Science and Economics,
and then received doctorate degrees in Medicine and in Law from Yale
University. He was President & CEO of NeoRx Corporation and
then CEPTYR, both biotechnology companies. He has been Chairman of
Aptein, a biotechnology company sold to Cambridge Antibody LTD, and of
Global Biosciences, a environmental remediation company. He has
also been on the Executive Committee of BIO, the industry trade
organization. He is inventor on 12 US patents, co-editor of two
books on cancer, and author of more than 60 publications.